IRIS
SCHEINER, BERNHARD
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.128
AS - Asia 772
EU - Europa 583
SA - Sud America 110
AF - Africa 57
Continente sconosciuto - Info sul continente non disponibili 35
Totale 2.685
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.050
RU - Federazione Russa 263
SG - Singapore 260
HK - Hong Kong 138
CN - Cina 137
BR - Brasile 86
IT - Italia 70
BD - Bangladesh 65
VN - Vietnam 61
GB - Regno Unito 55
FR - Francia 48
BJ - Benin 42
DE - Germania 41
CA - Canada 37
AT - Austria 27
IN - India 24
KR - Corea 24
JP - Giappone 21
MX - Messico 18
AR - Argentina 13
IQ - Iraq 10
NL - Olanda 10
PL - Polonia 9
SE - Svezia 9
UA - Ucraina 9
FI - Finlandia 8
ZA - Sudafrica 8
ES - Italia 7
IE - Irlanda 6
LT - Lituania 6
CR - Costa Rica 5
EC - Ecuador 5
CH - Svizzera 4
EE - Estonia 4
TR - Turchia 4
TT - Trinidad e Tobago 4
AE - Emirati Arabi Uniti 3
CO - Colombia 3
HN - Honduras 3
JM - Giamaica 3
MA - Marocco 3
PH - Filippine 3
GT - Guatemala 2
NP - Nepal 2
PT - Portogallo 2
SA - Arabia Saudita 2
SK - Slovacchia (Repubblica Slovacca) 2
SV - El Salvador 2
SY - Repubblica araba siriana 2
TH - Thailandia 2
TN - Tunisia 2
TW - Taiwan 2
UY - Uruguay 2
AM - Armenia 1
AZ - Azerbaigian 1
BE - Belgio 1
BG - Bulgaria 1
BS - Bahamas 1
CW - ???statistics.table.value.countryCode.CW??? 1
CZ - Repubblica Ceca 1
DZ - Algeria 1
EG - Egitto 1
GE - Georgia 1
ID - Indonesia 1
IL - Israele 1
KH - Cambogia 1
KZ - Kazakistan 1
LB - Libano 1
LC - Santa Lucia 1
MQ - Martinica 1
MY - Malesia 1
PK - Pakistan 1
PR - Porto Rico 1
PS - Palestinian Territory 1
UZ - Uzbekistan 1
VE - Venezuela 1
Totale 2.651
Salva come PNG Salva come JPEG
Città #
San Jose 167
Hong Kong 134
Singapore 132
Ashburn 101
Council Bluffs 100
Los Angeles 49
Cotonou 42
Santa Clara 39
Beijing 34
Columbus 30
Moscow 29
Phoenix 28
New York 26
Lauterbourg 25
Buffalo 24
Seoul 24
Tokyo 18
Ho Chi Minh City 17
Falkenstein 16
Vienna 15
Orem 14
São Paulo 14
Brooklyn 12
Chicago 12
Toronto 12
Dallas 11
Denver 11
Hanoi 11
Mexico City 11
Clifton 10
North Bergen 10
Nuremberg 10
Olathe 10
Boston 9
London 9
Stockholm 9
Warsaw 9
Frankfurt am Main 8
Tianjin 8
Atlanta 7
Chennai 7
Dublin 7
Helsinki 7
Assago 6
Florence 6
Manchester 6
Schaumburg 6
Da Nang 5
Dhaka 5
Johannesburg 5
Montreal 5
Poplar 5
Turin 5
Amsterdam 4
Bologna 4
Calgary 4
Houston 4
Milan 4
Richmond 4
San José 4
Shenzhen 4
Zurich 4
Agrolândia 3
Ankara 3
Baie-D'Urfé 3
Birmingham 3
Boardman 3
Brasília 3
Catania 3
Charlotte 3
Elk Grove Village 3
Honolulu 3
Las Vegas 3
Mumbai 3
Ottawa 3
Philadelphia 3
Pico Rivera 3
Providence 3
Roubaix 3
Secaucus 3
Sorocaba 3
Uberlândia 3
Washington 3
Augusta 2
Baghdad 2
Bangkok 2
Basra 2
Bexley 2
Cape Town 2
Chaguanas 2
Chengdu 2
Cleveland 2
Deiva Marina 2
Delhi 2
Grants Pass 2
Guangzhou 2
Guatemala City 2
Guayaquil 2
Haiphong 2
Hangzhou 2
Totale 1.465
Salva come PNG Salva come JPEG
Nome #
Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma versus other advanced solid tumours 142
Hepatic decompensation is the major driver of mortality in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: The impact of successful antiviral treatment 141
Impact of body mass index in patients receiving atezolizumab plus bevacizumab for hepatocellular carcinoma 128
Immunotherapy vs Best Supportive Care for Patients with Hepatocellular Cancer with Child-Pugh B Dysfunction 124
Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Prognostic Biomarkers in Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab 120
Baseline neutrophil-lymphocyte ratio and platelet-lymphocyte ratio appear predictive of immune treatment related toxicity in hepatocellular carcinoma 110
Impact of older age in patients receiving atezolizumab and bevacizumab for hepatocellular carcinoma 109
Disturbances in sodium and chloride homeostasis predict outcome in stable and critically ill patients with cirrhosis 104
Immune Checkpoint Inhibitors for Child-Pugh Class B Advanced Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis 104
Efficacy and safety of immune checkpoint inhibitor rechallenge in individuals with hepatocellular carcinoma 103
Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis: A real-world study 103
Outcome and management of patients with hepatocellular carcinoma who achieved complete response to immunotherapy-based systemic therapy 102
Outcomes of beta blocker use in advanced hepatocellular carcinoma treated with immune checkpoint inhibitors 100
Refining patient selection for next-generation immunotherapeutic early-phase clinical trials with a novel and externally validated prognostic nomogram 94
Immune checkpoint inhibitors in hepatocellular carcinoma: emerging challenges in clinical practice 93
Longitudinal Body Composition Identifies Hepatocellular Carcinoma With Cachexia Following Combined Immunotherapy and Target Therapy (CHANCE2213) 90
A meta-analysis and real-world cohort study on the sex-related differences in efficacy and safety of immunotherapy for hepatocellular carcinoma 90
Association between antibiotics and adverse oncological outcomes in patients receiving targeted or immune-based therapy for hepatocellular carcinoma 86
Progression patterns and therapeutic sequencing following immune checkpoint inhibition for hepatocellular carcinoma: An international observational study 83
Reproducible safety and efficacy of atezolizumab plus bevacizumab for HCC in clinical practice: Results of the AB-real study 82
PETAL protocol: A phase Ib study of pembrolizumab after transarterial chemoembolization in hepatocellular carcinoma 81
Efficacy and safety of atezolizumab/bevacizumab in patients with HCC after prior systemic therapy: A global, observational study 74
The Hammersmith Score Optimises Patient Selection and Predicts for Overall Survival in Early-Phase Cancer Trial Participants Independent of Tumour Burden 74
Artificial intelligence-based pathology as a biomarker of sensitivity to atezolizumab–bevacizumab in patients with hepatocellular carcinoma: a multicentre retrospective study 74
The systemic inflammatory response identifies patients with adverse clinical outcome from immunotherapy in hepatocellular carcinoma 73
Transversal psoas muscle thickness measurement is associated with response and survival in patients with HCC undergoing immunotherapy 57
Lenvatinib vs. sorafenib as second-line treatment post atezolizumab plus bevacizumab for hepatocellular carcinoma: The LEVIATHAN study 51
Tumor-infiltrating Neutrophils: Gatekeepers in Liver Cancer Immune Control 48
Efficacy of atezolizumab plus bevacizumab for unresectable HCC: Systematic review and meta-analysis of real-world evidence 45
Totale 2.685
Salva come PNG Salva come JPEG
Categoria #
all - tutte 11.400
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 11.400
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2023/202459 16 1 6 1 8 0 8 4 0 1 0 14
2024/2025468 8 0 30 2 6 35 57 60 102 58 22 88
2025/20261.645 64 43 79 165 217 129 234 204 125 136 133 116
2026/2027513 73 120 103 217 0 0 0 0 0 0 0 0
Totale 2.685